This Article Abstract Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Lebeche, D. Articles by Hajjar, R. Search for Related Content PubMed Articles by Lebeche, D. Articles by Hajjar, R. Social Bookmarking                         What's this?

Candesartan abrogates G protein-coupled receptors agonist-induced MAPK activation and cardiac myocyte hypertrophy

Cardiovascular Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

Zhao Bin Kang

Cardiovascular Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

Roger Hajjar

Cardiovascular Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA, hajjar@cvrc. mgh.harvard.edu

The renin-angiotensin-aldosterone system (RAAS) has been identified as a major contributor to the development of cardiac hypertrophy and the subsequent transition to heart failure. G protein-coupled receptors agonists such as angiotensin II (Ang II), endothelin-1 (ET-1) and phenylephrine (PE) have been implicated in hypertrophic responses in ventricular myocytes through the activation of several families of MAP kinases. In this study we examined the effect of candesartan, an Ang II type 1-(AT₁)-receptor antagonist, on cardiac hypertrophy by using cultured neonatal rat cardiomyocytes. Stimulation with Ang II (100 nM), ET-1 (100 nM) or PE (1 µM) induced marked increases in [³H]Leucine incorporation ( 50%), compatible with enhanced protein synthesis. The addition of candesartan abrogated the increase in [³H]Leucine incorporation in response not only to Ang II but also to ET-1 and PE. To elucidate the mechanisms involved in this antihypertrophic effect of candesartan, we studied the activation of p38-MAPK, extracellular signal-regulated kinases (ERK_1/2) and stress-activated protein kinases (SAPKs). Ang II, ET-1 and PE increased the phosphorylation levels of ERK_1/2, p54 ^SAPK and p46^SAPK and p38 in a time-dependent manner. This activation was completely blocked in the case of Ang II by pretreatment with candesartan. ET-1-induced activation of ERKs, SAPKs and p38 was also partially, but significantly, reduced by candesartan. PE-induced activation of SAPKs, but not ERKs and p38, was also reduced by candesartan. These results suggest that the hypertrophic response to ET-1 and PE, along with Ang II, is dependent upon a functioning AT₁-receptor and may be mediated by AT ₁ activation of the MAP kinases.

Key Words: candesartan • Ang II type 1 receptor blockers • MAP kinases • cardiac hypertrophy

References

• Chien KR, Zhu H., Knowlton KU et al.Transcriptional regulation during cardiac growth and development. Ann Rev Physiol 1993;55:77-95.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Sadoshima J., Izumo S.The cellular and molecular response of cardiac myocytes to mechanical stress. Ann Rev Physiol 1997;59:551-71.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Katz AM Cardiomyopathy of overload. A major determinant of prognosis in congestive heart failure. N Engl J Med 1990;322:100-10.[Web of Science][Medline] [Order article via Infotrieve]
• Sugden PH and Clerk A. Cellular mechanisms of cardiac hypertrophy. J Mol Med 1998; 76(11):725-46.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Sugden PH Signaling in myocardial hypertrophy: life after calcineurin? Circ Res 1999; 84: 633-46.[Free Full Text]
• Molketin JD, Lu JR,Antos CL et al.A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 1998; 93:215-28.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• De Windt LJ, Lim HW, Haq S., Force T., Molkentin JD Calcineurin promotes protein kinase C and c-Jun NH2-terminal kinase activation in the heart. Cross-talk between cardiac hypertrophic signaling pathways. J Biol Chem 2000; 275:13571-9.[Abstract/Free Full Text]
• Komuro I.,Yazaki Y. Control of cardiac gene expression by mechanical stress.Ann Rev Physiol 1993;55:55-75.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Yamazaki T., Komuro I., Kudoh S. et al. Endothelin-1 is involved in mechanical stress-induced cardiomyocyte hypertrophy. J Biol Chem 1996;271:3221-8.[Abstract/Free Full Text]
• Sadoshima J., Izumo S. Molecular characterization of Ang IIinduced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Critical role of the AT1 receptor subtype. Circ Res 1993;73:413-23.[Abstract/Free Full Text]
• Vogelsang M., Broede-Sitz A., Schafer E., Zerkowski HR, Brodde OE Endothelin ETA-receptors couple to inositol phosphate formation and inhibition of adenylate cyclase in human right atrium. J Cardiovasc Pharmacol 1994;23:344-7.[Web of Science][Medline] [Order article via Infotrieve]
• Knowlton KU, Michel MC, Itani M. et al. The alpha 1A-adrenergic receptor subtype mediates biochemical, molecular, and morphologic features of cultured myocardial cell hypertrophy. J Biol Chem 1993;268:15374-80.[Abstract/Free Full Text]
• Sadoshima J., Xu Y., Slayter HS, Izumo S. Autocrine release of Ang II mediates stretch-induced hypertrophy of cardiac myocytes in vitro. Cell 1993;75:977-84.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Van Heugten HA, De Jonge HW, Bezstarosti K., Sharma HS, Verdouw PD, Lamers JM Intracellular signaling and genetic reprogramming during agonist-induced hypertrophy of cardiomyocytes. Ann NY Acad Sci 1995;752:343-53.[Web of Science][Medline] [Order article via Infotrieve]
• Ito H., Hiroe M., Hirata Y. et al. Endothelin ETA receptor antagonist blocks cardiac hypertrophy provoked by hemodynamic overload. Circulation 1994;89:2198-03.[Abstract/Free Full Text]
• Unger T. Significance of angiotensin type 1 receptor blockade: why are angiotensin II receptor blockers different? Am J Cardiol 1999;84(10A): S-15S.
• Israili ZM Clinical pharmacokinetics of Ang II (AT1) receptor blockers in hypertension. J Hum Hypertension 2000;14(suppl.1):S73-S86.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Morsing P. Candesartan: a new-generation Ang II AT1 receptor blocker: pharmacology, antihypertensive efficacy, renal function, and renoprotection. J Am Soc Nephrol 1999;10:S248-S254.[Web of Science][Medline] [Order article via Infotrieve]
• Mitsunami K., Inoue S., Maeda K. et al. Three-month effects of candesartan cilexetil, an Ang II type 1 (AT1) receptor antagonist, on left ventricular mass and hemodynamics in patients with essential hypertension. Cardiovasc Drugs Ther 1998;12:469-74.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Tsuyuki RT,Yusuf S., Rouleau JL et al. Combination neuro-hormonal blockade with ACE inhibitors, angiotensin II antagonists and beta-blockers in patients with congestive heart failure: design of the Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study. Can J Cardiol 1997;13:1166-74.[Web of Science][Medline] [Order article via Infotrieve]
• Krombach RS, Clair MJ, Hendrick JW et al. Angiotensin converting enzyme inhibition, AT1 receptor inhibition, and combination therapy with pacing induced heart failure: effects on left ventricular performance and regional blood flow patterns. Cardiovasc Res 1998;38:631-45.[Abstract/Free Full Text]
• Makino N., Hata T., Sugano M., Dixon IM, Yanaga T. Regression of hypertrophy after myocardial infarction is produced by the chronic blockade of angiotensin type 1 receptor in rats. Mol Cell Cardiol 1996;28:507-17.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Kojima M., Shiojima I., Yamazaki T. et al. Ang II receptor antagonist TCV-116 induces regression of hypertensive left ventricular hypertrophy in vivo and inhibits the intracellular signaling pathway of stretch-mediated cardiomyocyte hypertrophy in vitro. Circulation 1994;89:2204-11.[Abstract/Free Full Text]
• See S., Stirling AL Candesartan cilexetil: an angiotensin IIreceptor blocker. Am J Health Syst Pharm 2000;57(8):739-46.[Abstract/Free Full Text]
• Nishikawa K., Naka T., Chatani F.,Yoshimura Y. Candesartan cilexetil: a review of its preclinical pharmacology. J Hum Hypertens 1997;11(suppl2):S9-S17.[CrossRef]
• Yoshimura M.,Yasue H. Hemodynamic and hormonal effects of the angiotensin II antagonist, candesartan cilexetil, in patients with congestive heart failure. Cardiology 2000; 93:175-82.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Riegger GA, Bouzo H., Petr P. et al. Improvement in exercise tolerance and symptoms of congestive heart failure during treatment with candesartan cilexetil. Symptom,Tolerability, Response to Exercise Trial of Candesartan Cilexetil in Heart Failure (STRETCH) Investigators. Circulation 2000;100:2224-30.[Web of Science]
• Yamazaki T., Komuro I., Kudoh S. et al. Ang II partly mediates mechanical stress-induced cardiac hypertrophy. Circ Res 1995;77:258-65.[Abstract/Free Full Text]
• Izumi Y., Kim S., Zhan Y., Namba M., Yasomoto H., Iwao H. Important role of Ang II-mediated c-Jun NH2-Terminal Kinase Activation in Cardiac Hypertrophy in Hypertensive Rats. Hypertension 2000; 36:511-6.[Abstract/Free Full Text]
• Yamazaki T.,Yazaki Y. Molecular basis of cardiac hypertrophy. Z Kardiol 2000; 89:1-6.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Gradman AH Long-Term Benefits of Angiotensin II Blockade: Is the Consensus Changing? Am J Cardiol 1999; 84:16S-21S.[Web of Science][Medline] [Order article via Infotrieve]
• Johnston CI Ang II Type 1 Receptor Blockade:A novel Therapeutic Concept. Blood Press Suppl 2000;1:9-13[Medline] [Order article via Infotrieve]
• Siragy HM, Inagami T., Ichiki T., Carey RM Sustained hypersensitivity to angiotensin II and its mechanism in mice lacking the subtype-2 (AT2) angiotensin receptor. Proc Natl Acad Sci USA 1999; 96:6506-10.[Abstract/Free Full Text]

Journal of Renin-Angiotensin-Aldosterone System, Vol. 2, No. 1 suppl, S154-S161 (2001)
DOI: 10.1177/14703203010020012701


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This Article Abstract Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Lebeche, D. Articles by Hajjar, R. Search for Related Content PubMed Articles by Lebeche, D. Articles by Hajjar, R. Social Bookmarking                         What's this?